Search Results - "Langdon, Ronald B."

Anti-diabetic efficacy and impact on amino acid metabolism of GRA1, a novel small-molecule glucagon receptor antagonist by Mu, James, Qureshi, Sajjad A, Brady, Edward J, Muise, Eric S, Candelore, Mari Rios, Jiang, Guoqiang, Li, Zhihua, Wu, Margaret S, Yang, Xiaodong, Dallas-Yang, Qing, Miller, Corey, Xiong, Yusheng, Langdon, Ronald B, Parmee, Emma R, Zhang, Bei B

“…Hyperglucagonemia is implicated in the pathophysiology of hyperglycemia. Antagonism of the glucagon receptor (GCGR) thus represents a potential approach to…”
Get full text

Effects of Peripherally Administered Neuromedin U on Energy and Glucose Homeostasis by Peier, Andrea M, Desai, Kunal, Hubert, James, Du, Xiaobing, Yang, Liming, Qian, Ying, Kosinski, Jennifer R, Metzger, Joseph M, Pocai, Alessandro, Nawrocki, Andrea R, Langdon, Ronald B, Marsh, Donald J

“…Neuromedin U (NMU) is a highly conserved peptide reported to modulate energy homeostasis. Pharmacological studies have shown that centrally administered NMU…”
Get full text

Efficacy and safety of the selective 11β-HSD-1 inhibitors MK-0736 and MK-0916 in overweight and obese patients with hypertension by Shah, Sukrut, Hermanowski-Vosatka, Anne, Gibson, Kendra, Ruck, Rae Ann, Jia, Gang, Zhang, John, Hwang, Peggy M T, Ryan, Nicholas W, Langdon, Ronald B, Feig, Peter U

“…11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) may be involved in several abnormalities associated with the metabolic syndrome. This study evaluated the…”
Get more information

Pharmacokinetic and pharmacodynamic properties of the glucokinase activator MK-0941 in rodent models of type 2 diabetes and healthy dogs by Eiki, Jun-ichi, Nagata, Yasufumi, Futamura, Mayumi, Sasaki-Yamamoto, Kaori, Iino, Tomoharu, Nishimura, Teruyuki, Chiba, Masato, Ohyama, Sumika, Yoshida-Yoshimioto, Riki, Fujii, Kenji, Hosaka, Hideka, Goto-Shimazaki, Hiroko, Kadotani, Akito, Ohe, Tomoyuki, Lin, Songnian, Langdon, Ronald B, Berger, Joel P

“…Glucokinase activators (GKAs) are small-molecule agents that enhance glucose sensing by pancreatic β cells and glucose metabolism by hepatocytes. There is…”
Get more information

Evaluation of pharmacokinetic parameters and dipeptidyl peptidase‐4 inhibition following single doses of sitagliptin in healthy, young Japanese males by Herman, Gary A., Mistry, Goutam C., Yi, Bingming, Bergman, Arthur J., Wang, Amy Q., Zeng, Wei, Chen, Li, Snyder, Karen, Ruckle, Jon L., Larson, Patrick J., Davies, Michael J., Langdon, Ronald B., Gottesdiener, Keith M., Wagner, John A.

“…WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Sitagliptin is an oral antihyperglycaemic agent that improves glycaemic control by inhibiting dipeptidyl peptidase‐4…”
Get full text

A small-molecule glucokinase activator lowers blood glucose in the sulfonylurea-desensitized rat by Ohyama, Sumika, Takano, Hiroki, Iino, Tomoharu, Nishimura, Teruyuki, Zhou, Yun-Ping, Langdon, Ronald B., Zhang, Bei B., Eiki, Jun-ichi

“…Glucokinase activators increase insulin release from pancreatic β-cells and hepatic glucose utilization by modifying the activity of glucokinase, a key enzyme…”
Get full text

Montelukast in the treatment of allergic rhinitis : An evidence-based review by NAYAK, Anjuli, LANGDON, Ronald B

“…Cysteinyl-leukotrienes (CysLTs) are endogenous mediators of inflammation and play an important role in allergic airway disease by stimulating…”
Get full text

Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes by Raz, Itamar, Chen, Yu, Wu, Mei, Hussain, Shehla, Kaufman, Keith D., Amatruda, John M., Langdon, Ronald B., Stein, Peter P., Alba, Maria

“…ABSTRACT Objective: The purpose of this study was to evaluate the efficacy and safety of sitagliptin as an add-on to metformin therapy in patients with…”
Get full text

A Phase I Pharmacokinetic and Pharmacodynamic Study of Dalotuzumab (MK-0646), an Anti-Insulin-like Growth Factor-1 Receptor Monoclonal Antibody, in Patients with Advanced Solid Tumors by ATZORI, Francesco, TABERNERO, Josep, DI COSIMO, Serena, BROWN, Holly, CLARK, Jason, HARDWICK, James S, BECKMAN, Robert A, HANLEY, William D, HSU, Karl, CALVO, Emiliano, ROSELLO, Susana, LANGDON, Ronald B, CERVANTES, Andrés, BASELGA, José, PRUDKIN, Ludmila, ANDREU, Jordi, RODRIGUEZ-BRAUN, Edith, DOMINGO, Amparo, GUIJARRO, Jorge, GAMEZ, Cristina, RODON, Jordi

“…Insulin-like growth factor-1 receptor (IGF-1R) mediates cellular processes in cancer and has been proposed as a therapeutic target. Dalotuzumab (MK-0646) is a…”
Get full text

Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial by Barzilai, Nir, Guo, Hua, Mahoney, Erin M., Caporossi, Suzanne, Golm, Gregory T., Langdon, Ronald B., Williams-Herman, Debora, Kaufman, Keith D., Amatruda, John M., Goldstein, Barry J., Steinberg, Helmut

“…Abstract Objective: Type 2 diabetes in the elderly is an important and insufficiently studied public health problem. This study evaluated sitagliptin…”
Get full text

A systematic review of in-hospital worsening heart failure as an endpoint in clinical investigations of therapy for acute heart failure by Fonseca, Cândida, Maggioni, Aldo Pietro, Marques, Filipa, Araújo, Inês, Brás, Daniel, Langdon, Ronald B., Lombardi, Carlo, Bettencourt, Paulo

“…In-hospital worsening heart failure (WHF) occurs frequently in patients hospitalized for acute heart failure (AHF) and has strongly negative prognostic…”
Get full text

Single-dose montelukast or salmeterol as protection against exercise-induced bronchoconstriction by Philip, George, Pearlman, David S, Villarán, César, Legrand, Catherine, Loeys, Tom, Langdon, Ronald B, Reiss, Theodore F

“…It has been previously established that montelukast provides protection against exercise-induced bronchoconstriction (EIB) after a single dose. The present…”
Get more information

Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea by Mohan, Viswanathan, Yang, Wenying, Son, Ho-Young, Xu, Lei, Noble, Liliane, Langdon, Ronald B, Amatruda, John M, Stein, Peter P, Kaufman, Keith D

“…Abstract The efficacy and safety of sitagliptin as monotherapy were evaluated in Chinese, Indian, and Korean patients with type 2 diabetes inadequately…”
Get full text

Erratum to “A systematic review of in-hospital worsening heart failure as an endpoint in clinical investigations of therapy for acute heart failure” [Int. J. Cardiol. 250 (2018) 215–222] by Fonseca, Cândida, Maggioni, Aldo Pietro, Marques, Filipa, Araújo, Inês, Brás, Daniel, Langdon, Ronald B., Lombardi, Carlo, Bettencourt, Paulo

Get full text

Effects of sugammadex on activated partial thromboplastin time and prothrombin time in healthy subjects by DE KAM, Pieter-Jan, GROBARA, Peter, PROHN, Marita, HÖPPENER, Floris, KLUFT, Cornelis, BURGGRAAF, Jacobus, LANGDON, Ronald B, PEETERS, Pierre

“…To assess the impact of sugammadex on activated partial thromboplastin time (APTT) and international normalized ratio for prothrombin time (PT(INR)) in healthy…”
Get full text

Disruption of retinogeniculate afferent segregation by antagonists to NMDA receptors by Hahm, Jong-On, Langdon, Ronald B, Sur, Mriganka

“…Afferent activity has an important role in the formation of connections in the developing mammalian visual system. But the extent to which the activity of…”
Get full text

Humoral immunity and delayed-type hypersensitivity in healthy subjects treated for 30 days with MK-7123, a selective CXCR2 antagonist by Seiberling, Michael, Kamtchoua, Thierry, Stryszak, Paul, Ma, Xuewen, Langdon, Ronald B, Khalilieh, Sauzanne

“…Antagonism of the chemokine receptor CXCR2 inhibits neutrophil trafficking and may thus be therapeutic in patients with chronic obstructive pulmonary disease…”
Get full text

Deficient Neurogenesis in Forebrain-Specific Presenilin-1 Knockout Mice Is Associated with Reduced Clearance of Hippocampal Memory Traces by Feng, Ruiben, Rampon, Claire, Tang, Ya-Ping, Shrom, David, Jin, Janice, Kyin, Maureen, Sopher, Bryce, Martin, George M, Kim, Seong-Hun, Langdon, Ronald B, Sisodia, Sangram S, Tsien, Joe Z

“…To examine the in vivo function of presenilin-1 ( PS1), we selectively deleted the PS1 gene in excitatory neurons of the adult mouse forebrain. These…”
Get full text

Pharmacokinetics of the novel PAR-1 antagonist vorapaxar in patients with hepatic impairment by Statkevich, Paul, Kosoglou, Teddy, Preston, Richard A., Kumar, Bharath, Xuan, Fengjuan, Trusley, Craig, Schiller, James E., Langdon, Ronald B., Cutler, David L.

“…Purpose To determine whether hepatic impairment has an effect on the pharmacokinetics (PK) of vorapaxar or M20, its main pharmacologically active metabolite…”
Get full text

Pharmacokinetic–pharmacodynamic studies of the 11β‐hydroxysteroid dehydrogenase type 1 inhibitor MK‐0916 in healthy subjects by Wright, D. Hamish, Stone, Julie A., Crumley, Tami M., Wenning, Larissa, Zheng, Wei, Yan, Kerri, Yang, Amy Yifan, Sun, Li, Cilissen, Caroline, Ramael, Steven, Hermanowski‐Vosatka, Anne, Langdon, Ronald B., Gottesdiener, Keith M., Wagner, John A., Lai, Eseng

“…Aims To characterize pharmacokinetic parameters of MK‐0916 and its safety and tolerability in lean, healthy male subjects following single and multiple oral…”
Get full text